The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome

Georgia D. Montouris, James Wheless, Tracy A. Glauser

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy that appears in childhood. LGS is characterized by a slow spike-wave pattern on electroencephalogram (EEG), cognitive impairment, and multiple seizure types. This mixture of seizure types, along with the need to use more than one type of medication, makes LGS one of the most complicated epilepsies to treat successfully. Recent developments in approved therapies for the treatment of LGS offer physicians more options, but also make developing a treatment strategy that minimizes adverse events more challenging. There are currently 5 treatment options for LGS: felbamate, lamotrigine, topiramate, rufinamide, and clobazam, and several others that are used off-label, each of which has benefits and limitations. There are several factors that must be considered when determining which medication to use when treating patients with LGS, including efficacy, which is assessed by seizure frequency, tolerability, and the anticipated duration of treatment. In this article, data supporting current treatment options are discussed, and important considerations about the treatment of LGS are reviewed.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalEpilepsia
Volume55
Issue numbers4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Seizures
felbamate
Therapeutics
Brain Diseases
Lennox Gastaut Syndrome
Electroencephalography
Epilepsy
Physicians
Cognitive Dysfunction
rufinamide
topiramate
clobazam
lamotrigine

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. / Montouris, Georgia D.; Wheless, James; Glauser, Tracy A.

In: Epilepsia, Vol. 55, No. s4, 01.01.2014, p. 10-20.

Research output: Contribution to journalArticle

Montouris, Georgia D. ; Wheless, James ; Glauser, Tracy A. / The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. In: Epilepsia. 2014 ; Vol. 55, No. s4. pp. 10-20.
@article{23513bffe4c447dbb6e8b034a1a9baef,
title = "The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome",
abstract = "Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy that appears in childhood. LGS is characterized by a slow spike-wave pattern on electroencephalogram (EEG), cognitive impairment, and multiple seizure types. This mixture of seizure types, along with the need to use more than one type of medication, makes LGS one of the most complicated epilepsies to treat successfully. Recent developments in approved therapies for the treatment of LGS offer physicians more options, but also make developing a treatment strategy that minimizes adverse events more challenging. There are currently 5 treatment options for LGS: felbamate, lamotrigine, topiramate, rufinamide, and clobazam, and several others that are used off-label, each of which has benefits and limitations. There are several factors that must be considered when determining which medication to use when treating patients with LGS, including efficacy, which is assessed by seizure frequency, tolerability, and the anticipated duration of treatment. In this article, data supporting current treatment options are discussed, and important considerations about the treatment of LGS are reviewed.",
author = "Montouris, {Georgia D.} and James Wheless and Glauser, {Tracy A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/epi.12732",
language = "English (US)",
volume = "55",
pages = "10--20",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "s4",

}

TY - JOUR

T1 - The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome

AU - Montouris, Georgia D.

AU - Wheless, James

AU - Glauser, Tracy A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy that appears in childhood. LGS is characterized by a slow spike-wave pattern on electroencephalogram (EEG), cognitive impairment, and multiple seizure types. This mixture of seizure types, along with the need to use more than one type of medication, makes LGS one of the most complicated epilepsies to treat successfully. Recent developments in approved therapies for the treatment of LGS offer physicians more options, but also make developing a treatment strategy that minimizes adverse events more challenging. There are currently 5 treatment options for LGS: felbamate, lamotrigine, topiramate, rufinamide, and clobazam, and several others that are used off-label, each of which has benefits and limitations. There are several factors that must be considered when determining which medication to use when treating patients with LGS, including efficacy, which is assessed by seizure frequency, tolerability, and the anticipated duration of treatment. In this article, data supporting current treatment options are discussed, and important considerations about the treatment of LGS are reviewed.

AB - Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy that appears in childhood. LGS is characterized by a slow spike-wave pattern on electroencephalogram (EEG), cognitive impairment, and multiple seizure types. This mixture of seizure types, along with the need to use more than one type of medication, makes LGS one of the most complicated epilepsies to treat successfully. Recent developments in approved therapies for the treatment of LGS offer physicians more options, but also make developing a treatment strategy that minimizes adverse events more challenging. There are currently 5 treatment options for LGS: felbamate, lamotrigine, topiramate, rufinamide, and clobazam, and several others that are used off-label, each of which has benefits and limitations. There are several factors that must be considered when determining which medication to use when treating patients with LGS, including efficacy, which is assessed by seizure frequency, tolerability, and the anticipated duration of treatment. In this article, data supporting current treatment options are discussed, and important considerations about the treatment of LGS are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=84908031427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908031427&partnerID=8YFLogxK

U2 - 10.1111/epi.12732

DO - 10.1111/epi.12732

M3 - Article

C2 - 25284033

AN - SCOPUS:84908031427

VL - 55

SP - 10

EP - 20

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - s4

ER -